Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis
- Integrated Phase I/lll study for proposed biosimilar denosumab to confirm matching efficacy, safety and immunogenicity with reference medicine[1]?
- Osteoporosis accounts for 8.9m bone fractures annually, including debilitating hip fractures -- number set to increase substantially over next two decades[2]
- Sandoz has eight marketed biosimilar medicines globally and 10+ molecules in the pipeline including proposed biosimilar denosumab
# # #
Novartis Global External Communications Email:?media.relations@novartis.comAntonio Ligi Novartis Global External Communications + 41 61 324 1374 (direct) Email:?antonio.ligi@novartis.com Chris Lewis Sandoz Global Communications +49 174 244 9501 (mobile) Email:?chris.lewis@sandoz.com | Michelle Bauman Sandoz Global Communications +1 973 714 8043 (mobile) Email:?michelle.bauman@sandoz.com |